CannPal’s aim is to be one of the first companies to provide veterinarians with GMP-produced and regulatory approved cannabinoid-derived therapeutics for pets.
Showing 25 of 224
A deal has been done with SUDA, a global leader in oro-mucosal drug delivery.
Yesterday, Medlab revealed it had made progress expanding cannabis-based medicines into Europe.
By having a European subsidiary, Medlab can save on drug registration fees.
THC Global has expanded into New Zealand's medicinal cannabis market.
The clinical trial partnership will examine the potential to use cannabinoid-based medications.
The opportunity is for ownership of a future full-scale cannabis growing facility in Canada.
The company's first product line is medicinal cannabis hard shell capsules.
The company is focused on developing a range of cannabinoid-based medical treatments.
The company is building a strong supply chain in anticipation of the launch of its proprietary manufactured products in 2019.
The company will now proceed with stage II of the human clinical trial.
Legalisation for the recreational use of cannabis in Canada on October 17, 2018, will result in the accelerated growth of this nascent industry.
The company had a healthy cash balance of $4.72 million at the end of the quarter.
Canadian subsidiary Crystal Mountain is expanding its range of hydroponics equipment to meet expected demand.
The medical cannabis company is vertically integrated from 'farm to pharma'.
A strategic review will see more focus on the largest global markets for medicinal cannabis.
Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.
The online education resources aim to bring awareness to medical professionals.
The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.
AusCann is transitioning from a start-up company focused on product development to a pharmaceutical production and sales business.
The study is being led by one of Australia’s leading sleep research centres.
CannPal plans to take the results from its recently commenced phase 1A and B studies to file an Investigational New Animal Drug application with the FDA.
Shares of the health sciences company soar sharply in both Canada and New York
The company aims to release its first medicinal cannabis products in FY2019.
The licence opens up potential international markets for its cannabis-based medicines.